Stay updated with breaking news from Durable Response. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL 28.09.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Release BOS...
Autoimmune toxicities, while common following treatment with cancer immunotherapies, are not well-characterized in patients treated with BRAF/MEK inhibitors. Emerging data suggest that autoimmune effects may be linked with superior responses to both treatment modalities; however, there is little evidence describing mechanisms of immune-related toxicity for patients on BRAF/MEK inhibitors. Here we describe the experience of a 59-year-old HLA-A2, A29, B27-positive male patient with recurrent/metastatic melanoma. After progression on checkpoint inhibitor therapy, he was treated with dabrafenib/tr...
Breaking news headlines about Lung Cancer linking to 1,000s of websites from around the world